BG 2205
Alternative Names: BG-2205; CD19-BCMA CAR-T Cell Therapy - Guangzhou Bio-gene TechnologyLatest Information Update: 23 Dec 2025
At a glance
- Originator Guangzhou Bio-gene Technology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Connective tissue disorders
Most Recent Events
- 03 Sep 2025 Clinical trials in Connective tissue disorders (In children, In adolescents, In adults, In the elderly, Treatment-experienced) in China (IV) (NCT07152223)
- 18 Apr 2022 Guangzhou Bio-gene Technology receives 23rd China Patent Excellence Award for its invention patent, "A Bispecific Chimeric Antigen Receptor Targeting BCMA and CD19 and Its Applications"